Are Exosomes FDA Approved? What Practitioners Need to Understand
One of the most common questions from practitioners evaluating exosome biologics is straightforward: are exosomes FDA approved? The answer requires more than a yes or no — it requires understanding what FDA approval means, what the current regulatory framework actually covers, and what that means for sourcing decisions.
This article summarizes the current FDA regulatory position on exosome products for licensed practitioners. It is not legal advice. Practitioners should consult qualified legal counsel for guidance specific to their practice and jurisdiction.
The FDA's Current Position on Exosomes
The FDA has stated clearly in public safety communications that there are currently no FDA-approved exosome products. The FDA has further stated that exosomes used to treat diseases or conditions in humans are generally regulated as drugs and biological products and are subject to premarket review requirements.
FDA has issued multiple warning letters to exosome suppliers for marketing exosome products for disease treatment or therapeutic uses without the required regulatory authorization. These warning letters have cited claims related to tissue repair, inflammation, wound care, joint conditions, neurological conditions, and other therapeutic applications as evidence that the products were being marketed as unapproved drugs.
What the HCT/P Framework Covers — and What It Does Not
Under 21 CFR Part 1271, certain human cells, tissues, and cellular and tissue-based products (HCT/Ps) may be regulated under the Section 361 pathway — meaning they are regulated under the Public Health Service Act rather than as drugs requiring premarket approval. To qualify, a product must meet all of the following criteria:
- Minimally manipulated
- Intended for homologous use — performing the same basic function in the recipient as in the donor
- Not combined with a drug or device
- Does not have a systemic effect and is not dependent on the metabolic activity of living cells for its primary function
Products that do not meet all of these criteria are regulated as drugs and/or biologics and require premarket review — including an Investigational New Drug application or Biologics License Application — before being marketed for therapeutic use.
What FDA Enforcement Has Focused On
FDA warning letters to exosome suppliers have repeatedly cited the following as violations:
Disease and condition claims
Marketing exosome products for osteoarthritis, joint repair, wound healing, hair loss, neurological conditions, TBI, long COVID, anti-aging, and similar applications has been cited as evidence of unapproved drug marketing.
Mechanism claims treated as therapeutic claims
Claims about anti-inflammatory effects, immune modulation, tissue regeneration, angiogenesis, stem cell activation, and similar biological mechanisms have been cited even when framed as educational content.
Contradictory "research only" disclaimers
FDA cited suppliers who labeled products as "for research only" while simultaneously marketing them for patient care applications. A disclaimer does not cure a therapeutic marketing claim if the surrounding content contradicts it.
Cosmetic positioning contradicted by disease language
FDA cited at least one supplier who claimed cosmetic use while still referencing disease applications on the same website. Cosmetic positioning does not protect against enforcement if disease claims appear elsewhere.
The Safe Lane for Exosome Marketing
Based on FDA's public guidance and enforcement history, the safest lane for exosome products on public-facing websites is:
- Topical cosmetic use only — appearance-focused language about the look of skin texture, visible radiance, post-procedure cosmetic support
- No disease names — do not reference osteoarthritis, hair loss, inflammation, wound healing, or any condition on exosome marketing pages
- No mechanism claims — anti-inflammatory, immune modulation, stem cell activation, angiogenesis, tissue regeneration are all mechanism claims that function as therapeutic claims under FDA's framework
- Clear not-FDA-approved statement — prominently stated, not buried in a footer disclaimer
What This Means for Sourcing
The regulatory framework creates a documentation standard for suppliers. Practitioners sourcing exosome biologics should require:
- Products positioned clearly as topical cosmetic biologics — not therapeutic products
- Supplier marketing that does not make disease or mechanism claims
- Lot-specific Certificate of Analysis with NTA-verified particle count, sterility, mycoplasma, and endotoxin
- AATB-accredited, FDA-registered tissue establishment operating under cGTP standards (21 CFR Part 1271)
- No "injectable-grade" language on a topical cosmetic product
Source Compliant Topical Cosmetic Exosome Biologics
Lot-specific CoAs, NTA-verified particle counts, and cGTP-compliant manufacturing (21 CFR Part 1271) — available to licensed professionals upon credential verification.
Enroll Your Practice Today → Contact Our TeamFrequently Asked Questions
Are there any FDA-approved exosome products?
No. The FDA has stated there are currently no FDA-approved exosome products in the United States. Any supplier claiming their exosome product is FDA-approved should be evaluated with significant caution.
Can I use exosome biologics in my practice?
All clinical decisions are at the sole discretion of the licensed practitioner in accordance with applicable federal and state regulations. This article is not legal or clinical advice. Practitioners should consult qualified legal counsel regarding compliance with applicable regulations in their jurisdiction.
What should I look for in a compliant exosome supplier?
A compliant supplier will position their exosome products as topical cosmetic biologics only, will not make disease or mechanism claims in their marketing, will provide lot-specific CoA documentation with every order, and will maintain AATB accreditation and operate under cGTP-compliant manufacturing standards (21 CFR Part 1271). They will never describe their products as injectable-grade or use therapeutic language.